Reported signals
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate
Registration status unknownDrugalgemeen
17,624
reports (FAERS)
73.2%
reported as serious
395
fatal reports (2.2%)
0
signals above threshold
2026-07
last updated
Signal ranking · ROR
What stands out in the reports.
No disproportionate signals with sufficient data to plot. This may indicate the substance has too few reports, or that reported effects are in line with background rates.
Interpretation
Summary not yet available — will be auto-generated.
Label versus report
On the label
No signals currently mapped to the label.
Newly reported
No novel signals above threshold.
Recall history · 0 on record
No recalls on record.
Compare within ALGEMEEN
implant
Reports3,932,418
Compare with bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate →
minoxidil foam 5% (womens)
Reports3,436,075
Compare with bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate →
dental implant
Reports3,208,206
Compare with bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate →
Source & citation
HealthProves. bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate — reported signals. Retrieved 2026-07-05. Source: openFDA (FAERS). healthproves.com/bictegravir-sodium-emtricitabine-and-tenofovir-alafenamide-fumarate/
FAERS17,624 records
Retrieved2026-07-05
MethodROR / disproportionality